ES2121788T3 - Anticuerpos dirigidos contra cd3. - Google Patents
Anticuerpos dirigidos contra cd3.Info
- Publication number
- ES2121788T3 ES2121788T3 ES91917169T ES91917169T ES2121788T3 ES 2121788 T3 ES2121788 T3 ES 2121788T3 ES 91917169 T ES91917169 T ES 91917169T ES 91917169 T ES91917169 T ES 91917169T ES 2121788 T3 ES2121788 T3 ES 2121788T3
- Authority
- ES
- Spain
- Prior art keywords
- ser
- tyr
- gly
- asp
- asn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LIGANTES CON UNA AFINIDAD DE ENLACE PARA EL ANTIGENO CD3 QUE TIENEN, AL MENOS, UN CDR CUYO ORIGEN ES DISTINTO RESPECTO A LA REGION DE LA ESTRUCTURA VARIABLE Y/O A LA REGION CONSTANTE DEL LIGANTE; AL MENOS, EL UNICO CDR QUE SE SELECCIONA DE LAS SECUENCIAS DE AMINOACIDOS: (A) SER TR ARG ASN LIS FE DE LOS MISMOS, TIENEN VALOR TERAPEUTICO, PARTICULARMENTE EN EL CONTROL DEL RECHAZO A INJERTOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909021679A GB9021679D0 (en) | 1990-10-05 | 1990-10-05 | Antibody preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2121788T3 true ES2121788T3 (es) | 1998-12-16 |
Family
ID=10683287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES91917169T Expired - Lifetime ES2121788T3 (es) | 1990-10-05 | 1991-10-04 | Anticuerpos dirigidos contra cd3. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0504350B1 (es) |
JP (1) | JP3081641B2 (es) |
KR (1) | KR100245564B1 (es) |
AT (1) | ATE169058T1 (es) |
AU (1) | AU651623B2 (es) |
CA (1) | CA2070659C (es) |
DE (1) | DE69129896T2 (es) |
ES (1) | ES2121788T3 (es) |
GB (2) | GB9021679D0 (es) |
NZ (1) | NZ240080A (es) |
WO (1) | WO1992006193A1 (es) |
ZA (1) | ZA917960B (es) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9021679D0 (en) * | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
US6106835A (en) * | 1991-04-19 | 2000-08-22 | Tanox, Inc. | Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators |
US6129916A (en) * | 1991-04-19 | 2000-10-10 | Tanox, Inc. | Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates |
US5872222A (en) * | 1991-04-19 | 1999-02-16 | Tanox Biosystems, Inc. | Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants |
CA2065658A1 (en) * | 1991-04-19 | 1992-10-20 | Tse-Wen Chang | Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators |
US6197298B1 (en) | 1991-04-19 | 2001-03-06 | Tanox, Inc. | Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals |
US5817308A (en) * | 1994-02-14 | 1998-10-06 | University Of Rochester | Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance |
US7153508B2 (en) | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
US7175847B1 (en) | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
CA2288943C (en) | 1997-04-30 | 2011-02-01 | De Novo Enzyme Corporation | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections |
US6103466A (en) * | 1997-07-14 | 2000-08-15 | University Of Liege | Double-muscling in mammals |
DE69841139D1 (de) | 1997-07-14 | 2009-10-22 | Univ Liege | Mutationen im myostatingen steigern muskelmasse in säugetieren |
GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
US6531125B1 (en) | 1999-03-02 | 2003-03-11 | Twinstrand Therapeutics Inc. | Antiviral ricin-like proteins |
CA2305716A1 (en) | 1999-05-28 | 2000-11-28 | University Of Guelph | Method for assay of wbpm |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
AU2003221575B2 (en) | 2002-05-02 | 2010-06-10 | Dalia Barsyte | Teneurin C-terminal associated peptides (TCAP) and uses thereof |
WO2005012526A1 (en) | 2003-08-04 | 2005-02-10 | The Hospital For Sick Children | Lafora's disease gene |
US7427670B2 (en) | 2003-12-19 | 2008-09-23 | Cytochroma Inc. | Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof |
TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
ATE530198T1 (de) | 2005-02-16 | 2011-11-15 | Univ Zuerich | Verfahren zur behandlung von krebs unter verwendung eines immunotoxins mit einer exotoxin- a-gruppierung, bei der eine furinschnittstelle durch eine von mmp-2 oder mmp-9 gespaltene krebsassoziierte proteasestelle ersetzt ist |
TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-22(il-22)之抗體及其用途 |
TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
KR101495549B1 (ko) | 2006-07-13 | 2015-02-25 | 와이어쓰 엘엘씨 | 당단백질의 생산 |
PT2486941T (pt) * | 2006-10-02 | 2017-05-30 | Squibb & Sons Llc | Anticorpos humanos que ligam a cxcr4 e utilizações dos mesmos |
RU2009111138A (ru) | 2006-10-12 | 2010-11-20 | Вайет (Us) | Способы и композиции с уменьшенной опалесценцией |
CA2666317C (en) | 2006-11-03 | 2013-08-06 | Wyeth | Glycolysis-inhibiting substances in cell culture |
CA2669084A1 (en) | 2006-11-10 | 2008-05-29 | Massachusetts Institute Of Technology | Pak modulators |
DE102006062398A1 (de) | 2006-12-20 | 2008-06-26 | Edi (Experimentelle & Diagnostische Immunologie) Gmbh | Verfahren zur Erkennung und/oder Charakterisierung zellulärer Aktivitätsmuster, Verwendung von Toll-like-Rezeptor-Liganden (TLR-Liganden) und ein Kit |
JP5586235B2 (ja) | 2007-03-02 | 2014-09-10 | ワイス・エルエルシー | ポリペプチドの産生のための細胞培養における銅およびグルタミン酸塩の使用 |
JP2012504939A (ja) | 2008-09-23 | 2012-03-01 | ワイス・エルエルシー | 架橋結合タンパク質による活性化シグナルの産生を予測するための方法 |
AU2009314311B2 (en) | 2008-10-29 | 2013-01-10 | Ablynx N.V. | Methods for purification of single domain antigen binding molecules |
BR122018013284B1 (pt) | 2008-10-29 | 2022-03-03 | Ablynx N.V | Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab |
WO2010091182A2 (en) | 2009-02-04 | 2010-08-12 | Molecular Innovations | Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein |
US8765916B2 (en) | 2009-04-29 | 2014-07-01 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | ERG monoclonal antibodies |
CA2766861A1 (en) | 2009-07-09 | 2011-01-13 | F. Hoffmann-La Roche Ag | In vivo tumor vasculature imaging |
CN102858796B (zh) | 2010-03-03 | 2016-05-11 | 不列颠哥伦比亚大学 | 寡聚体特异性淀粉样蛋白β表位和抗体 |
AU2011277983C1 (en) | 2010-07-16 | 2016-09-29 | Ablynx Nv | Modified single domain antigen binding molecules and uses thereof |
EP2420250A1 (en) | 2010-08-13 | 2012-02-22 | Universitätsklinikum Münster | Anti-Syndecan-4 antibodies |
CA2807607A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
US20130273055A1 (en) | 2010-11-16 | 2013-10-17 | Eric Borges | Agents and methods for treating diseases that correlate with bcma expression |
KR20140018299A (ko) | 2011-03-30 | 2014-02-12 | 아블린쓰 엔.브이. | Tnf-알파에 대한 단일 도메인 항체를 이용하여 면역 장애를 치료하는 방법 |
EP2768944B2 (en) | 2011-10-21 | 2023-11-22 | Pfizer Inc. | Addition of iron to improve cell culture |
EP3718556A3 (en) | 2012-08-31 | 2020-12-30 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
AU2013312529A1 (en) | 2012-09-05 | 2015-04-16 | The University Of Birmingham | Target peptides for colorectal cancer therapy and diagnostics |
JP2015533127A (ja) | 2012-10-08 | 2015-11-19 | セント ジュード チルドレンズ リサーチ ホスピタルSt. Jude Children’s Research Hospital | ニューロピリン1:セマフォリン軸を介した、制御性t細胞の安定性および機能の制御に基づく療法 |
US20160000893A1 (en) | 2012-12-13 | 2016-01-07 | University Of Virginia Patent Foundation | Target peptides for ovarian cancer therapy and diagnostics |
WO2015013671A1 (en) | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
EP3119876A1 (en) | 2014-03-19 | 2017-01-25 | Pfizer Inc. | Method of cell culture |
US10654908B2 (en) | 2014-04-15 | 2020-05-19 | University Of Virginia Patent Foundation | Isolated T cell receptors and methods of use therefor |
EP3172235A2 (en) | 2014-07-25 | 2017-05-31 | Cytomx Therapeutics Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
MA45352A (fr) | 2015-08-07 | 2018-06-13 | Univ Birmingham | Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer |
WO2017051347A2 (en) | 2015-09-23 | 2017-03-30 | Pfizer Inc. | Cells and method of cell culture |
GB201520191D0 (en) | 2015-11-16 | 2015-12-30 | Cancer Rec Tech Ltd | T-cell receptor and uses thereof |
JP7253923B2 (ja) | 2016-04-05 | 2023-04-07 | ファイザー・インク | 細胞培養プロセス |
KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
CA3056182A1 (en) | 2017-03-16 | 2018-09-20 | Pfizer Inc. | Tyrosine prototrophy |
WO2018215535A1 (en) | 2017-05-23 | 2018-11-29 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
KR20200047702A (ko) | 2017-09-15 | 2020-05-07 | 브리스톨-마이어스 스큅 컴퍼니 | 관심 폴리펩티드 대규모 생산 동안의 온라인 바이오매스 정전용량 모니터링 |
WO2019145475A2 (en) | 2018-01-25 | 2019-08-01 | Acm Biolabs Pte Ltd | Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof |
WO2019178489A1 (en) | 2018-03-16 | 2019-09-19 | Bristol-Myers Squibb Company | Metabolic enzyme activity and disulfide bond reduction during protein production |
FI3775909T3 (fi) | 2018-03-26 | 2023-08-01 | Glycanostics S R O | Välineitä ja menetelmiä proteiinin glykoprofiloimiseksi |
US20220105176A1 (en) | 2018-09-12 | 2022-04-07 | Acm Biolabs Pte Ltd | Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof |
US20220073942A1 (en) | 2018-12-06 | 2022-03-10 | Pfizer Inc. | Cells with reduced inhibitor production and methods of use thereof |
US20220332799A1 (en) | 2019-09-04 | 2022-10-20 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Herv inhibitors for use in treating tauopathies |
BR112023021224A2 (pt) | 2021-04-12 | 2024-01-16 | Acm Biolabs Pte Ltd | Polimerossomas compreendendo polinucleotídeo encapsulado solúvel e lipídio ionizável, bem como métodos de produção e usos dos mesmos |
CA3228822A1 (en) | 2021-08-26 | 2023-03-02 | Jan Tkac | Glycoprotein biomarkers for diagnosing cancer |
WO2023041565A1 (en) | 2021-09-14 | 2023-03-23 | Glycanostics S.R.O | Use of lectins to determine mammaglobin-a glycoforms in breast cancer |
WO2023079058A1 (en) | 2021-11-05 | 2023-05-11 | Yokogawa Insilico Biotechnology Gmbh | Cell culture with reduced production of lactate |
WO2023148598A1 (en) | 2022-02-02 | 2023-08-10 | Pfizer Inc. | Cysteine prototrophy |
CN115073602B (zh) * | 2022-05-30 | 2023-10-03 | 苏州百道医疗科技有限公司 | 一种抗cd3重组兔单克隆抗体及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI105320B (fi) * | 1988-04-04 | 2000-07-31 | Oncogen | Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9021679D0 (en) * | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
-
1990
- 1990-10-05 GB GB909021679A patent/GB9021679D0/en active Pending
-
1991
- 1991-10-03 NZ NZ240080A patent/NZ240080A/en not_active IP Right Cessation
- 1991-10-04 JP JP03516117A patent/JP3081641B2/ja not_active Expired - Fee Related
- 1991-10-04 WO PCT/GB1991/001726 patent/WO1992006193A1/en active IP Right Grant
- 1991-10-04 ZA ZA917960A patent/ZA917960B/xx unknown
- 1991-10-04 ES ES91917169T patent/ES2121788T3/es not_active Expired - Lifetime
- 1991-10-04 DE DE69129896T patent/DE69129896T2/de not_active Expired - Lifetime
- 1991-10-04 AU AU85468/91A patent/AU651623B2/en not_active Expired
- 1991-10-04 CA CA002070659A patent/CA2070659C/en not_active Expired - Lifetime
- 1991-10-04 AT AT91917169T patent/ATE169058T1/de not_active IP Right Cessation
- 1991-10-04 GB GB9121126A patent/GB2249310B/en not_active Revoked
- 1991-10-04 EP EP91917169A patent/EP0504350B1/en not_active Expired - Lifetime
- 1991-10-04 KR KR1019920701339A patent/KR100245564B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
GB2249310A (en) | 1992-05-06 |
DE69129896D1 (de) | 1998-09-03 |
EP0504350B1 (en) | 1998-07-29 |
JP3081641B2 (ja) | 2000-08-28 |
NZ240080A (en) | 1995-05-26 |
GB9121126D0 (en) | 1991-11-13 |
CA2070659A1 (en) | 1992-04-06 |
AU651623B2 (en) | 1994-07-28 |
KR100245564B1 (ko) | 2000-02-15 |
GB2249310B (en) | 1994-08-03 |
GB9021679D0 (en) | 1990-11-21 |
CA2070659C (en) | 2001-04-24 |
KR927003816A (ko) | 1992-12-18 |
JPH05502384A (ja) | 1993-04-28 |
AU8546891A (en) | 1992-04-28 |
DE69129896T2 (de) | 1998-12-10 |
WO1992006193A1 (en) | 1992-04-16 |
ATE169058T1 (de) | 1998-08-15 |
ZA917960B (en) | 1993-04-05 |
EP0504350A1 (en) | 1992-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2121788T3 (es) | Anticuerpos dirigidos contra cd3. | |
ATE384792T1 (de) | Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern | |
ES2106195T3 (es) | Anticuerpo igg aglicosilado anti cd3. | |
EP0724456A4 (en) | ANTIBODIES AGAINST CD40 | |
CA2212750A1 (en) | Humanized antibodies against cd3 | |
ATE301471T1 (de) | Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation | |
SE9304060D0 (sv) | Sätt att selektera specifika bakteriofager | |
GR1002306B (el) | Αναλυση και διαταξη συγκολλησεως στηλης. | |
HK1025738A1 (en) | Lo-cd2a antibody and uses thereof for inhibiting tcell activation and proliferation | |
DE69129460D1 (de) | Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK | |
DK0812206T3 (da) | Fremgangsmåde til stimulering af en immunrespons | |
ATE191568T1 (de) | Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine | |
DE3485712D1 (de) | Monoklonale antikoerper gegen menschliche nierenkrebsantigene und verfahren. | |
DE3888604D1 (de) | Monoklonale Antikörper gegen Antithrombinbindende Substanz und seine Verwendungen. | |
DE3570677D1 (en) | Acino-foetal differentiation proteins associated with cancer of the pancreas, antiserum and monoclonal antibodies against these proteins and processes for their preparation | |
DE59207362D1 (de) | Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung | |
ES2013665A6 (es) | Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso. | |
Loy et al. | Correspondence re: TS Loy, AA Diaz-Arias, JT Bickel. Value of BCA-225 in the cytologic diagnosis of malignant effusions: an immunocytochemical study of 197 cases. Mod Pathol 3: 294, 1990 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 504350 Country of ref document: ES |